| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 28.94 | 1720 |
| Intrinsic value (DCF) | 3.21 | 102 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 166.51 | 10372 |
INmune Bio, Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company pioneering immunotherapies that reprogram the innate immune system to combat cancer and neurodegenerative diseases. Headquartered in Boca Raton, Florida, INmune Bio focuses on developing innovative treatments for hematologic malignancies, solid tumors, and chronic inflammation, with key programs like INKmune (targeting ovarian cancer and myelodysplastic syndrome), INB03 (for hematologic and solid tumors), and XPro1595 (for Alzheimer’s disease). Leveraging strategic partnerships with institutions like Xencor, Inc. and the University of Pittsburgh, the company aims to address unmet medical needs in oncology and neurology. With a market cap of approximately $169 million, INmune Bio operates in the high-growth biotechnology sector, where advancements in immunotherapy continue to drive investor interest. Its pipeline targets large addressable markets, positioning it as a potential disruptor in next-generation immune-oncology and neurodegenerative therapies.
INmune Bio presents a high-risk, high-reward opportunity for investors focused on clinical-stage biotech. The company’s novel immunotherapy platforms (INKmune, INB03, XPro1595) target significant unmet needs in oncology and Alzheimer’s, but its negative EPS (-$2.08) and operating cash flow (-$33.4M in FY2024) reflect heavy R&D spending typical of pre-revenue biotech firms. With $20.9M in cash and minimal debt ($384K), near-term liquidity appears manageable, but dilution risk remains given its burn rate. The stock’s high beta (1.64) signals volatility, aligning with its clinical trial-dependent valuation. Success in ongoing trials could unlock partnerships or buyout potential, but failure risks are amplified by its single-asset concentration in early-stage pipelines.
INmune Bio competes in the crowded immunotherapy space by targeting innate immune reprogramming—a niche distinct from checkpoint inhibitors (e.g., Keytruda) or CAR-T therapies. Its lead asset, INKmune, differentiates by activating natural killer (NK) cells to treat resistant cancers, a mechanism with fewer competitors than T-cell therapies. However, the Alzheimer’s candidate XPro1595 faces stiff competition from amyloid-targeting drugs like Biogen’s Leqembi, though its neuroinflammation approach could offer a差异化 pathway if proven effective. Financially, INmune’s $169M market cap is dwarfed by larger peers (e.g., Xencor at ~$1.4B), limiting resource access for trials. The company’s partnerships with academic institutions provide R&D leverage but lack the commercial infrastructure of rivals with approved products. Competitive advantages include first-mover potential in NK cell priming (INKmune) and a dual focus on oncology/neurodegeneration, though clinical validation is pending. Risks include pipeline attrition and competition from well-funded peers advancing similar modalities (e.g., NKTR-255 by Nektar Therapeutics).